Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Phosphodiesterase type 5 inhibitor abuse: a critical review.

Lowe G, Costabile R.

Curr Drug Abuse Rev. 2011 Jun;4(2):87-94. Review.

PMID:
21696344
2.

10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.

Lowe G, Costabile RA.

J Sex Med. 2012 Jan;9(1):265-70. doi: 10.1111/j.1743-6109.2011.02537.x. Epub 2011 Oct 24.

PMID:
22023666
3.

Phosphodiesterase 5 inhibitors for erectile dysfunction.

Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE.

Ann Pharmacother. 2005 Jul-Aug;39(7-8):1286-95. Epub 2005 Jun 7. Review.

PMID:
15941818
4.

Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?

Aliferis K, Petropoulos IK, Farpour B, Matter MA, Safran AB.

Ophthalmologica. 2012;227(2):85-9. doi: 10.1159/000333824. Epub 2011 Dec 7.

PMID:
22156704
5.

2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.

Shindel AW.

J Sex Med. 2009 Sep;6(9):2352-64; quiz 2365-6. doi: 10.1111/j.1743-6109.2009.01447.x.

PMID:
19735356
6.

The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.

Gökçe A, Halis F, Demirtas A, Ekmekcioglu O.

BJU Int. 2011 Apr;107(8):1274-7. doi: 10.1111/j.1464-410X.2010.09646.x. Epub 2010 Sep 7.

7.

Phosphodiesterase type 5 inhibitors: the day after.

Hatzimouratidis K, Hatzichristou D.

Eur Urol. 2007 Jan;51(1):75-88; discussion 89. Epub 2006 Aug 1. Review.

PMID:
16949200
8.

Phosphodiesterase inhibitors in Raynaud's phenomenon.

Levien TL.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1388-93. Epub 2006 Jul 11. Review.

PMID:
16835313
9.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
11.

A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Hatzimouratidis K, Hatzichristou DG.

Drugs. 2005;65(12):1621-50. Review.

PMID:
16060698
12.

Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.

Fleshner N, Harvey M, Adomat H, Wood C, Eberding A, Hersey K, Guns E.

J Urol. 2005 Aug;174(2):636-41; discussion 641; quiz 801.

PMID:
16006928
13.

Phosphodiesterase 5 inhibitors in male sexual dysfunction.

Kuthe A.

Curr Opin Urol. 2003 Sep;13(5):405-10. Review.

PMID:
12917517
14.

Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.

Taylor J, Baldo OB, Storey A, Cartledge J, Eardley I.

BJU Int. 2009 May;103(10):1392-5. doi: 10.1111/j.1464-410X.2008.08328.x. Epub 2009 Jan 20.

15.

Monitoring by LC-MS/MS of 48 compounds of sildenafil, tadalafil, vardenafil and their analogues in illicit health food products in the Korean market advertised as enhancing male sexual performance.

Lee JH, Kim NS, Han KM, Kim SH, Cho S, Kim WS.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(11):1849-57. doi: 10.1080/19440049.2013.826878. Epub 2013 Sep 2.

PMID:
23998781
16.

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks.

Jackson G, Arver S, Banks I, Stecher VJ.

Int J Clin Pract. 2010 Mar;64(4):497-504. doi: 10.1111/j.1742-1241.2009.02328.x. Epub 2010 Jan 18. Review.

17.

Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.

Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD.

Mol Pharmacol. 2004 Jul;66(1):144-52.

18.
19.

Internet-ordered viagra (sildenafil citrate) is rarely genuine.

Campbell N, Clark JP, Stecher VJ, Goldstein I.

J Sex Med. 2012 Nov;9(11):2943-51. doi: 10.1111/j.1743-6109.2012.02877.x. Epub 2012 Aug 27.

PMID:
22925379
20.

Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.

Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, Schermuly RT, Weissmann N, Seeger W, Grimminger F.

J Am Coll Cardiol. 2004 Oct 6;44(7):1488-96.

Supplemental Content

Support Center